Exact Sciences Reports Fourth-Quarter 2012 Financial Results

Exact Sciences Reports Fourth-Quarter 2012 Financial Results

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NAS: EXAS) today announced its financial results for the quarter and year ended Dec. 31, 2012.

Exact reported total revenues of $1.0 million for the fourth quarter of 2012 and the fourth quarter of 2011. Total revenues for the year ended Dec. 31, 2012, were $4.1 million, compared to $4.2 million for the year ended Dec. 31, 2011.

Exact reported a net loss of ($14.0) million, or ($0.22) a share, for the fourth quarter of 2012. The company had a net loss of ($9.9) million, or ($0.18) a share, for the same period of 2011. The net loss for the year ended Dec. 31, 2012, was ($52.4) million, or ($0.88) a share. The company's net loss for the year 2011 was ($28.7) million, or ($0.54) a share.

Operating expenses for the quarter ended Dec. 31, 2012, were $15.1 million, compared to $11.0 million for the fourth quarter of 2011. Operating expenses for full-year 2012 totaled $56.8 million, compared to $33.0 million during 2011. Operating expenses for the quarter and year ended Dec. 31, 2012, increased from the same periods a year ago primarily because of the ongoing clinical trial of the company's non-invasive colorectal cancer screening test.

Exact ended 2012 with cash, cash equivalents and marketable securities of $108.1 million, compared to $93.4 million at Dec. 31, 2011.

"We continue to make good progress towards completing the FDA submission for our non-invasive, stool-DNA-based colorectal cancer screening test," said Kevin T. Conroy, the company's president and chief executive. "We remain confident that the clinical trial will deliver strong results, and continue to actively and systematically prepare for the test's commercialization."

Fourth-Quarter Conference Call & Webcast

Company management will host a conference call and webcast on Wednesday, Feb. 20, 2013, at 10 a.m. ET to discuss fourth-quarter results. The webcast will be available at www.exactsciences.com. Domestic callers should dial 877-212-6082 and international callers should dial 707-287-9332. An archive of the webcast and a replay of the conference call will be available at www.exactsciences.com or by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the conference call and replay is 10728603. The conference call, webcast and replay are open to all interested parties.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company's website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections.Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results of our pivotal clinical trial, expectations concerning our ability to secure FDA approval of our Cologuard test, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy.Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Selected Unaudited Financial Information
Condensed Statements of Operation Data

(Amounts in thousands, except per share data)

Three Months EndedTwelve Months Ended
December 31,December 31,
Product royalty fees$-$6$-$20
License fees 1,036  1,036  4,144  4,143 
Cost of revenue:
Product royalty fees -  6  -  24 
Gross profit: 1,036  1,036  4,144  4,139 
Operating Expenses:
Research and development10,4397,67242,13121,968
General and administrative2,8152,2069,9008,137
Sales and marketing 1,824  1,094  4,755  2,857 
 15,078  10,972  56,786  32,962 
Loss from operations(14,042)(9,936)(52,642)(28,823)
Interest income7438262169
Interest expense(20)(6)(41)(21)
Net loss$(13,988)$(9,904)$(52,421)$(28,675)
Net loss per share - basic and diluted$(0.22)$(0.18)$(0.88)$(0.54)
Weighted average common shares
outstanding - basic and diluted 63,582  53,647  59,481  52,512 
Selected Unaudited Financial Information
Condensed Balance Sheet Data
(Amounts in thousands)
December 31,December 31,
Cash and cash equivalents$13,345$35,781
Marketable securities94,77657,580
Prepaid expenses and other current assets5931,034
Property and equipment, net 3,405  2,558 
Total assets$112,119 $96,953 
Liabilities and stockholders' equity
Total current liabilities$11,455$7,977
Long term debt1,0001,000
Long term accrued interest6342
Obligations under capital lease, net of current portion711-
Deferred license fees, less current portion2954,439
Total stockholders' equity 98,595  83,495 
Total liabilities and stockholders' equity$112,119 $96,953 

The Luminis Group, Ltd. for Exact Sciences Corp.
Rod Hise, 608-807-4607

KEYWORDS:   United States  North America  Wisconsin


The article Exact Sciences Reports Fourth-Quarter 2012 Financial Results originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story